Fundraising Fox

Orexigen Therapeutics

La Jolla, US · Founded 2019 · Delaware corporation · 146 employees on LinkedIn · 5 known investors

Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases. The company works within the healthcare and pharmaceutical industry to address patient health challenges.

BiotechHealthtech

Founders & leadership

PK
Preston KlassenExecutive
JH
Joseph HaganExecutive
MN
Michael NarachiExecutive
TC
Thomas CannellExecutive

Board

EW
Eckard WeberBoard directorVenture Partner at Domain Associates
BH
Brian H. Doveyin𝕏Board directorPartner at Domain Associates
LC
Louis C BockBoard director
PJ
Patrick J MahaffyBoard director
LS
Lota S ZothBoard director
PK
Peter K HonigBoard director
WL
Wendy L DixonBoard director
DJ
David J EndicottBoard director

Investors · 5

Cross Creek AdvisorsSalt Lake City
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Sofinnova VenturesMenlo Park · $100K – $15M
Domain AssociatesreportedPrinceton · $200K – $15Mvia Brian Dovey · board
Domain PartnersreportedPrinceton

Reported raises · per SEC filings

Form D private placements

$274.6M disclosed across 3 rounds · 2015–2017

▶$49.6MraisedMar 2017 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Deborah JornDirector
  • Thomas LynchExecutive Officer
  • Jason KeyesExecutive Officer
  • David J EndicottDirector
  • Patrick J MahaffyDirector
  • Thomas CannellExecutive Officer
  • Louis C BockDirector
  • Peter K HonigDirector
  • Peter FlynnExecutive Officer
  • Brian H. DoveyDirector
  • Michael NarachiExecutive Officer, Director
  • Lota S ZothDirector
Offering amount
$49.6M
Amount sold
$49.6M
Sales commissions
$1.6M
First sale
Feb 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$165MraisedMar 2016 · 21 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Louis C BockDirector
  • Eckard WeberDirector
  • Michael NarachiExecutive Officer, Director
  • Lota S ZothDirector
  • Thomas CannellExecutive Officer
  • Preston KlassenExecutive Officer
  • David J EndicottDirector
  • Thomas LynchExecutive Officer
  • Brian H. DoveyDirector
  • Patrick J MahaffyDirector
  • Heather AceExecutive Officer
  • Peter K HonigDirector
Offering amount
$330M
Amount sold
$165M
Sales commissions
$5M
Placement agents
Leerink Partners LLC
First sale
Mar 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$60MraisedSep 2015 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Preston KlassenExecutive Officer
  • Joseph HaganExecutive Officer
  • Eckard WeberDirector
  • Brian H. DoveyDirector
  • Louis C BockDirector
  • Patrick J MahaffyDirector
  • Lota S ZothDirector
  • Peter K HonigDirector
  • Michael NarachiExecutive Officer, Director
  • Wendy L DixonDirector
  • David J EndicottDirector
  • Thomas CannellExecutive Officer
Offering amount
$90M
Amount sold
$60M
First sale
Sep 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Form Health55 shared keywordsForm Health offers clinician-led obesity and cardiometabolic care combining a physician-directed care team (physicians, advanced practice providers, and registered dietitians) with nutrition, behavioral health, physical activity guidance, and FDA-approved GLP-1 medications. It provides employers with predictable access to obesity management medications and outcomes data, while delivering personalized weight-loss and long-term health support to individuals.

Companies competing with Orexigen Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

No magic pill for obesity: Orexigen files for bankruptcy | BioPharma Divebiopharmadive.com · Mar 2018Orexigen Therapeutics announces expansion of distributorship agreement with Biologix FZCO for Contrave to Egypt | Reutersreuters.com · Jul 2017

Frequently asked questions

What does Orexigen Therapeutics do?
Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases. The company works within the healthcare and pharmaceutical industry to address patient health challenges.
Who are Orexigen Therapeutics's investors?
Orexigen Therapeutics's investors include Cross Creek Advisors, New Enterprise Associates (NEA), Sofinnova Ventures, Domain Associates, Domain Partners.
How much funding has Orexigen Therapeutics raised?
Orexigen Therapeutics has disclosed $274.6M raised across 3 rounds.
Where is Orexigen Therapeutics headquartered?
Orexigen Therapeutics is headquartered in La Jolla, US.